Literature DB >> 26049774

Headache in Drug-Induced Aseptic Meningitis.

Dagny Holle1, Mark Obermann.   

Abstract

Drug-associated headache is a quite common phenomenon, e.g. as a side effect of distinct substances such as nitric oxide or as a result of medication overuse of analgesic drugs. A different drug-associated headache entity is headache in drug-induced aseptic meningitis (DIAM). This is a rare disorder and only described in few case reports or smaller case series. One of the main clinical features of DIAM despite fever is headache. Based on the literature, no typical or even pathognomonical clinical presentation of this headache entity can be described. Sometimes, migrainous features might be present, and treatment response to triptans was reported in single case reports. Headache in DIAM seems to be emerging from sterile meningeal inflammation, which is suggested to represent the underlying pathology in DIAM. Headache in DIAM usually ceases when treated sufficiently, mainly through termination or withdrawal of the causing agent. Migraine as a predisposing factor of DIAM has been discussed previously but remains unproven.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26049774     DOI: 10.1007/s11916-015-0505-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  25 in total

Review 1.  The challenge of drug-induced aseptic meningitis.

Authors:  G Moris; J C Garcia-Monco
Journal:  Arch Intern Med       Date:  1999-06-14

2.  Trimethoprim-sulfamethoxazole-induced aseptic meningitis.

Authors:  Charles Wambulwa; Salome Bwayo; Adeyinka O Laiyemo; Fredric Lombardo
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

3.  Acute aseptic meningitis inducing migraine-like attacks in a 7-year-old child.

Authors:  C Vollono; A Capuano; I Lazzareschi; A Ruggiero; G Attinà; P Maurizi; G Della Marca; P Mariotti
Journal:  Eur J Neurol       Date:  2006-05       Impact factor: 6.089

Review 4.  The challenge of drug-induced aseptic meningitis revisited.

Authors:  German Morís; Juan Carlos Garcia-Monco
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

5.  Aseptic inflammatory meningeal reaction manifesting as a migrainous syndrome.

Authors:  E Stamboulis; M Spengos; A Rombos; A Haidemenos
Journal:  Headache       Date:  1987-09       Impact factor: 5.887

6.  Ibuprofen may induce meningitis in (NZB X NZW)F1 mice.

Authors:  S Berliner; A Weinberger; Y Shoenfeld; U Sandbank; B Hazaz; H Joshua; M Rosen; J Pinkhas
Journal:  Arthritis Rheum       Date:  1985-01

7.  Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors.

Authors:  E A Sekul; E J Cupler; M C Dalakas
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

Review 8.  Migraine pain, meningeal inflammation, and mast cells.

Authors:  Dan Levy
Journal:  Curr Pain Headache Rep       Date:  2009-06

9.  Possible valacyclovir-related neurotoxicity and aseptic meningitis.

Authors:  Jacqueline L Olin; Joseph L Gugliotta
Journal:  Ann Pharmacother       Date:  2003-12       Impact factor: 3.154

10.  Headache associated with aseptic meningitis.

Authors:  M Lamonte; S D Silberstein; J F Marcelis
Journal:  Headache       Date:  1995-10       Impact factor: 5.887

View more
  3 in total

1.  Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis.

Authors:  Kevin Bihan; Nicolas Weiss; Hélène Théophile; Christian Funck-Brentano; Bénédicte Lebrun-Vignes
Journal:  Br J Clin Pharmacol       Date:  2019-08-01       Impact factor: 4.335

Review 2.  Recurrent Meningitis.

Authors:  Jon Rosenberg; Benjamin T Galen
Journal:  Curr Pain Headache Rep       Date:  2017-07

Review 3.  Intravenous Immunoglobulin-Induced Aseptic Meningitis-A Narrative Review of the Diagnostic Process, Pathogenesis, Preventative Measures and Treatment.

Authors:  Anna Kretowska-Grunwald; Maryna Krawczuk-Rybak; Malgorzata Sawicka-Zukowska
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.